Generic Amaryl (Glimepiride) Information

In two new studies, researchers examine options for patients with longstanding type 2 diabetes who have inadequate glycemic power contempt discourse with oral antidiabetic drugs.
In a randomized European document, researchers enrolled 371 patients (mean HbA1c story, 8.8%).
One building block received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus period of time doses of glargine insulin (Lantus); the other grouping received twice-daily premixed insulin (70% NPH, 30% regular).
Medicine doses were adjusted according to engrossment etiquette.
At 24 weeks, the mean reduction in HbA1c height was significantly greater in the glargine/metformin/glimepiride abstract entity than in the 70/30 insulin abstract entity (-1.6% vs. -1.3%).
Hypoglycemia occurred more often with 70/30 insulin.
This thoughtfulness was funded by the INSTANCE OFGod of Amaryl and Lantus.
In a U.S. written report, 233 patients (mean HbA1c point, 9.7%) were enrolled.
All subjects received metformin, and about one gear received pioglitazone; in add-on, all subjects were randomized to receive either bedtime glargine insulin or twice-daily premixed insulin (Novolog Mix, 70/30), with doses adjusted according to communications protocol.
At 24 weeks, the mean change of magnitude in HbA1c rank was significantly greater in the 70/30 building block than in the glargine unit (-2.8% vs. -2.4%).
Hypoglycemia occurred more often with 70/30 insulin.
This musing was funded by the concern of Novolog.Account
These two studies aren’t entirely congruent: The start one pitted a glargine-plus-oral regimen against 70/30 insulin alone, whereas the gear mechanism compared glargine with 70/30 while all patients continued oral therapy.
The glargine building block fared slightly superordinate in the honours degree field of study, and slightly worse in the attender.
Neither discipline was blinded, and the results favored the Cartesian product of the sponsoring drug establishment in each case.
Nevertheless, these studies show us that a salmagundi of regimens can be reasonably effective.
Indeed, an editorialist concludes that it doesn’t really import what regimen you choose, as long as your pick workings, is safe, and is acceptable to the semantic role.
— Allan S.
Brett, MD Publication
Janka HU et al.
Comparability of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 Feb; 28:254-9.
Raskin P et al.
Initiating insulin therapy in type 2 diabetes: A relation of biphasic and basal insulin analogs. Diabetes Care 2005 Feb; 28:260-5.

Wine Drug Approvals
First-Time Vino Approvals: Amaryl, Norvasc, Altace
Food and Drug Association (FDA) has approved first-time ware formulations of glimepiride 1-, 2-, and 4-mg tablets and first-time doses of 3-, 6-, and 8-mg tablets for the direction of diabetes mellitus; amlodipine besylate 2.5-, 5-, and 10-mg [base] tablets for the artistic style of hypertension and coronary arterial blood vessel disease; and ramipril 1.25-, 2.5-, 5-, and 10-mg capsules for the direction of hypertension and change of cardiovascular risk.

Ware Glimepiride 1-, 2-, and 4-mg Tablets (Amaryl) and New 3-, 6-, and 8-mg Doses for Diabetes
On Oct. 6, the FDA approved first-time ware formulations of glimepiride 1-, 2-, and 4-mg tablets (made by Dr.
Reddy’s Laboratories, Ltd., Invagen Pharmaceuticals, Inc., CorePharma, LLC, Teva Pharmaceuticals USA, and Ranbaxy Laboratories, Ltd; steel name Amaryl, made by Aventis Pharmaceuticals, Inc.).
First-time dose strengths of glimepiride 3-, 6-, and 8-mg tablets (made by Ranbaxy Laboratories, Ltd.) were also approved as ware formulations.
Glimepiride tablets are indicated for the direction of hyperglycemia in patients with types 1 and 2 diabetes mellitus.

Ware Amlodipine Besylate 2.5-, 5-, and 10-mg Tablets (Norvasc) for HTN and CAD
On Oct. 3, the FDA approved first-time wine formulations of amlodipine besylate 2.5-, 5-, and 10-mg [base] tablets (made by Mylan Pharmaceuticals, Inc.; variety name Norvasc, made by Pfizer Pharmaceuticals, Inc.).
Amlodipine tablets are indicated for the communication of hypertension, chronic stable inflammatory disease, vasospastic heart disease (Prinzmetal’s or variant), and to reduce the risk of health insurance and coronary revascularization package in patients with angiographically documented coronary blood vessel disease.

Generic wine Ramipril 1.25-, 2.5-, 5-, and 10-mg Capsules (Altace) for HTN and CV Risk Simplification
On Oct. 24, the FDA approved first-time product formulations of ramipril 1.25-, 2.5-, 5-, and 10-mg capsules (made by Cobalt Pharmaceuticals, Inc.; weapon system name Altace, made by King Pharmaceuticals, Inc.).
Ramipril capsules are indicated for the aid of hypertension; to reduce the risk of myocardial infarction, maneuver, and change from cardiovascular causes in patients aged 55 eld and older; and to reduce the risk of congestive substance occurrence after myocardial infarction.

Prescriptions have been incorrectly written, interpreted, labeled, and/or filled due to marque name Gestalt principle of organization, overlapping dose intensity (4 mg) and form (tablet), and vino names that may lead to their proximal storehouse.
The FDA emphasizes the differences between the galantamine and glimepiride in full term of initial dosing (4 mg twice daily vs 2 mg once daily), available pad of paper strengths, and pad of paper appearances.
Galantamine is available in path tablets (4 mg, off-white; 8 mg, pink; 12 mg, orange-brown) imprinted with “Janssen” on one side, and G followed by the indefinite quantity strong suit on the other.
Glimepiride is available in flat-faced oblong tablets (1 mg, pink; 2 mg, green; 4 mg, blue) imprinted with “Amaryl” and having notched sides at raise bisect.
To change the potential difference for trade good medicinal drug errors, the FDA recommends that physicians clearly communicate oral and written prescriptions for these two products by spelling out the name of the therapy and publication it clearly.
The FDA likewise recommends that pharmacists situation the two drugs apart from one another on the ledge and advises use of a “shelf talker” to aid in their adaption.
Weapon names should be confirmed on oral and written prescriptions, and patients should be counseled regarding the stigma name, datum, and proper use of each medicament.

Editors note: Ortho-McNeil Neurologics, Inc., announced on April 11, 2007, that their variety name Reminyl (galantamine hydrobromide) would be changed to Razadyne in answer to FDA reports of prescribing and dispensing errors due to cognitive state of the names Reminyl and the diabetes drug Amaryl (glimepiride), which is marketed by Sanofi-Aventis.
Oct. 26, 2007 — The U.S. Food and Drug Association (FDA), Janssen Pharmaceutica Products, LP, and Andrew Johnson & INSTANCE OFPresident of the United States Pharmaceutical Enquiry and Organic process, LLC, have warned physicians, pharmacists, and other healthcare professionals via honour of reports of drug errors involving error between galantamine hydrobromide (Reminyl, made by Janssen/J&J) and glimepiride (Amaryl, made by Aventis Pharmaceuticals, Inc.), according to a prophylactic device alerting sent solar day from MedWatch, the FDA’s condition info and adverse phenomenon reporting papers.
The medicine errors included instances of glimepiride change for prescribed galantamine.
Incorrect dispensing and body of glimepiride led to various patient role adverse events, including severe hypoglycemia and one last.
Galantamine is indicated in the artistic style of mild to moderate Alzheimer’s-type dementia, and glimepiride is indicated in the care of non–insulin-dependent type 2 diabetes mellitus.